Amgen Inc.
AMGN
주식 순위
#71
Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California,... Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories, including inflammatory conditions, oncology and hematology, bone health, cardiovascular diseases, nephrology, and neuroscience. Its extensive portfolio features a range of significant pharmaceutical products. Notable examples include Enbrel, prescribed for conditions like plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, which helps cancer patients by reducing the risk of infection linked to a low white blood cell count; Prolia, utilized in postmenopausal women to combat osteoporosis; and Xgeva, designed to prevent skeletal-related complications. Otezla offers relief for adult patients suffering from plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease. Aranesp addresses anemia and low red blood cell counts, while KYPROLIS is employed to treat patients with relapsed or refractory multiple myeloma. Furthermore, Repatha plays a vital role in lowering the incidence of major cardiovascular events such as myocardial infarction, stroke, and coronary revascularization. Amgen's comprehensive product lineup also encompasses Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. The company distributes its therapies worldwide, primarily serving healthcare providers, including physicians and their clinics, dialysis centers, hospitals, and pharmacies. Distribution is facilitated through pharmaceutical wholesale distributors, complemented by direct-to-consumer channels. Amgen actively engages in strategic collaborations. It has partnered with entities such as Novartis Pharma AG, UCB, Bayer HealthCare LLC, BeiGene, Ltd., Eli Lilly and Company, Datos Health, and Verastem, Inc., to jointly assess VS-6766 when combined with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. Another key alliance involves Kyowa Kirin Co., Ltd., for the co-development and commercialization of KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody targeting atopic dermatitis and other autoimmune conditions. Additionally, Amgen maintains research and development partnerships with Neumora Therapeutics, Inc. and Plexium, Inc.
주가
$436.87
마지막 동기화: 2026-10-20
시가총액
$236.19B
변동 (1일)
2.81%
변동 (1년)
45.07%
국가
US
거래 Amgen Inc. (AMGN)
카테고리
Healthcare
Amgen Inc. (AMGN)의 매출
Jun 2026 기준 매출 TTM: $38.13B
Amgen Inc.의 최신 재무 보고서에 따르면 회사의 현재 수익 (TTM)은 $38.13B입니다. 2024년에 회사는 $33.42B의 수익을 올렸으며 이는 2023년의 $28.19B 대비 증가입니다. 수익은 상품이나 서비스를 판매하여 얻은 총 수입을 의미합니다. 수익과는 달리 비용이 차감되지 않습니다.
Amgen Inc.의 수익 기록 (2000 ~ 2026)
매년 말 매출
| 연도 | 매출 | 변화 |
|---|---|---|
| 2026 (TTM) | $38.13B | 3.74% |
| 2025 | $36.75B | 9.95% |
| 2024 | $33.42B | 18.57% |
| 2023 | $28.19B | 7.09% |
| 2022 | $26.32B | 1.32% |
| 2021 | $25.98B | 2.18% |
| 2020 | $25.42B | 8.83% |
| 2019 | $23.36B | -1.62% |
| 2018 | $23.75B | 3.93% |
| 2017 | $22.85B | -0.62% |
| 2016 | $22.99B | 6.14% |
| 2015 | $21.66B | 7.97% |
| 2014 | $20.06B | 7.43% |
| 2013 | $18.68B | 8.17% |
| 2012 | $17.27B | 10.80% |
| 2011 | $15.58B | 3.51% |
| 2010 | $15.05B | 2.81% |
| 2009 | $14.64B | -2.41% |
| 2008 | $15.00B | 1.57% |
| 2007 | $14.77B | 3.53% |
| 2006 | $14.27B | 14.79% |
| 2005 | $12.43B | 17.82% |
| 2004 | $10.55B | 26.26% |
| 2003 | $8.36B | 51.29% |
| 2002 | $5.52B | 37.54% |
| 2001 | $4.02B | 16.45% |
| 2000 | $3.45B | 0.00% |
유사 기업 또는 경쟁사의 매출
| 회사 | 매출 | 매출 차이 | 국가 |
|---|---|---|---|
| $79.67B | 108.96% |
US
|
|
| $99.34B | 160.55% |
US
|
|
| $64.39B | 68.88% |
US
|
|
| $66.40B | 74.16% |
US
|
|
| $77.52B | 103.33% |
CH
|
